All In Biotech

BLA 017067 · Fresenius Kabi USA

Chorionic Gonadotropin

Gonadotropin, Chorionic · Injection

Last checked: Nov 20, 2026Latest source record: Oct 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

Mar 5, 1973

Approved uses

17

Original approval plus efficacy supplements

Registered trials

1,292

340 Phase 3, 113 recruiting

FAERS reports

561

417 serious, 26 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 11, 2025.

INDICATIONS AND USAGE: HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ‘‘NORMAL’’ DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. 1. Prepubertal cryptorchidism not due to anatomical obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases, the response is temporary. Therapy is usually instituted between the ages four and nine. 2. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. 3. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 1981 Supplement 42 · Efficacy
  • Aug 13, 1980 Supplement 38 · Efficacy
  • Aug 13, 1980 Supplement 32 · Efficacy
  • Aug 13, 1980 Supplement 30 · Efficacy
  • Aug 13, 1980 Supplement 37 · Efficacy
  • Aug 13, 1980 Supplement 29 · Efficacy
  • Aug 13, 1980 Supplement 35 · Efficacy
  • Aug 13, 1980 Supplement 33 · Efficacy
  • Dec 18, 1979 Supplement 28 · Efficacy
  • Dec 18, 1979 Supplement 34 · Efficacy
  • Dec 18, 1979 Supplement 39 · Efficacy
  • Dec 18, 1979 Supplement 31 · Efficacy
  • Mar 9, 1978 Supplement 24 · Efficacy
  • Mar 9, 1978 Supplement 25 · Efficacy
  • Mar 9, 1978 Supplement 17 · Efficacy
  • Mar 9, 1978 Supplement 23 · Efficacy
  • Mar 5, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 20,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 5,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 15,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 10,000 UNITS/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gonadotropin" as an intervention, any sponsor and status, largest first.

All 1,292 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome130
  • drug ineffective38
  • drug exposure during pregnancy37
  • off label use33
  • ascites31
  • ectopic pregnancy31
  • dyspnoea27
  • nausea27
  • headache26
  • abdominal distension25
  • pain24
  • pleural effusion24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200527
200627
200745
200818
200929
201026
201153
201278
201314
201415
20155
201627
201716
201820
201920
202024
202120
202227
202317
202416
202510
202618

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Chorionic Gonadotropin (Chorionic Gonadotropin, Human)

2024 spending

$481K

Beneficiaries

146

598 claims

Per beneficiary

$3,291

$295.34 per unit

View as table
YearSpending
2020$460,023
2021$387,422
2022$450,809
2023$565,015
2024$480,519

Part B: Chorionic Gonadotropin* (Chorionic Gonadotropin, Human*) · HCPCS J0725

2024 spending

$337K

Beneficiaries

241

6,848 claims

Per beneficiary

$1,398

2024 ASP limit $21.87 per unit

View as table
YearSpending
2020$398,283
2021$504,301
2022$416,524
2023$327,448
2024$336,980

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,168 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.